NP-delivered intervention fails to reduce early symptom burden during chemo
the ONA take:
A nurse practitioner (NP)-delivered symptom management intervention did not appear to reduce symptom burden compared with standard care among patients initiating chemotherapy for nonmetastatic cancer, a new study published in the journal Cancer has shown.
For the study, researchers sought to determine whether an NP-delivered symptom management intervention would reduce patient-reported symptom burden among patients initiating chemotherapy for nonmetastatic cancer.
Researchers enrolled 120 patients with nonmetastatic breast, colorectal, or lung cancer and randomly assigned them to receive standard care alone or standard care plus the intervention.
Patients assigned to the intervention group received telephone calls from their oncology NP during the week after each of the first two visits for chemotherapy administration.
Results showed that 50.8% of patients reported at least one physical symptom at the time of the first chemotherapy administration visit. Researchers found that the number of symptoms, symptom distress, and satisfaction with care increased, while the risk for anxiety symptoms decreased.
The likelihood of depression symptoms did not change over time. There was no difference in the reduction of patient-reported symptom burden between the two arms.
The findings suggest that it is important to continue identifying strategies to improve symptom management, particularly early symptoms, during chemotherapy for patients with nonmetastatic disease.
A nurse practitioner-delivered symptom management intervention did not appear to reduce symptom burden.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Open Hysterectomy Survival Rates Edge Minimally Invasive Procedures for Cervical Cancer
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|